Neelima Reddy, MD
Gastroenterology · Baton Rouge, LANPI 1770796138
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Phathom Pharmaceuticals, Inc. accounts for 64.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $15,324 and has fallen 70.3% since, to $4,554 in 2025.
Across 280 payments — averaging $83.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$15K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Bausch Health US, LLC$2K
- Bristol Myers Squibb$433
- Pfizer$359
- plus $2K from 18 others
Across 40 payments — averaging $5893.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$168K
- Pfizer$40K
- E.r. Squibb & Sons, L.L.C.$15K
- Bristol Myers Squibb$13K
What the payments were for
- Consulting fees$3,74016%
- Speaking & faculty fees$13,33057%
- Travel & lodging$8103%
- Food & beverage$5,31423%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 34 | $15,015 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $2,369 |
| AbbVie(2 entities) | 109 | $1,952 |
| Bausch Health US, LLC | 2 | $1,600 |
| Bristol Myers Squibb | 29 | $433 |
| Pfizer | 20 | $359 |
| Johnson & Johnson | 25 | $325 |
| Boston Scientific | 9 | $283 |
| Sanofi | 5 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $148 |
| Regeneron Healthcare Solutions, Inc. | 1 | $134 |
| Ferring Pharmaceuticals Inc. | 9 | $118 |
| Madrigal Pharmaceuticals | 4 | $76 |
| Intercept Pharmaceuticals, Inc. | 3 | $39 |
| Pharmacosmos Therapeutics Inc. | 2 | $39 |
| Gilead | 3 | $39 |
| Ardelyx, Inc. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| UCB, Inc. | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $12 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,241 in reported general payments places this provider in the 85th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 36 | $31,350 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 106 | $7,134 |
| TrulancePlecanatide | 13 | $7,133 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 42 | $6,868 |
| Sucralfate | 22 | $3,448 |
| Pantoprazole Sodium | 287 | $3,091 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 24 | $2,879 |
| Lubiprostone | 15 | $2,154 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,083 |
| Ondansetron OdtOndansetron | 46 | $1,545 |
| Colestipol Hcl | 21 | $1,366 |
| Esomeprazole Magnesium | 32 | $946 |
| Omeprazole | 87 | $882 |
| Dicyclomine Hcl | 76 | $607 |
| Azathioprine | 18 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,952 | $31,35036 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $2,369 | $7,13313 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $118 | $6,86842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Baton Rouge
- Jonathon ChapmanBaton Rouge$998K
- Gia LandryBaton Rouge$511K
- Gregory GaspardBaton Rouge$86K
- Ronald LeoBaton Rouge$9K
- Conar FittonKenner$955K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.